KALV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Kalvista Pharmaceuticals Inc (KALV) is not a strong buy for a beginner, long-term investor at this moment. While the company shows potential in its product growth and has positive analyst ratings, the recent financial performance, insider and hedge fund selling, and lack of strong trading signals suggest holding off on an immediate investment.
The stock's MACD is negative and expanding downward, indicating bearish momentum. RSI is neutral at 48.174, suggesting no clear trend. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading near its support level (S1: 19.268) with resistance at R1: 20.873.
Analysts are maintaining positive ratings with increased price targets, citing strong product growth and sustainable revenue from refills. The bullish moving averages also indicate some positive momentum.
Hedge funds and insiders are selling significantly, with hedge fund selling up 7382.63% and insider selling up 751.28%. Financial performance in Q4 2025 shows a significant drop in net income (-210.62% YoY) and EPS (-186.41% YoY). The options market sentiment is bearish, and there is no recent positive news or congressional trading activity.
In Q4 2025, revenue remained flat YoY at $35.39M, but net income dropped significantly to -$49.39M (-210.62% YoY), and EPS fell to -0.89 (-186.41% YoY). Gross margin remained strong at 94.77%, but the overall financial performance indicates challenges in profitability.
Analysts maintain a positive outlook, with recent price target adjustments to $28, $35, and $42, reflecting confidence in the company's product growth and market potential. However, the stock's financial struggles and insider selling may temper this optimism.
